

Degradation behaviors and in-vivo biocompatibility of a rare earth- and aluminum-free magnesium-based stent

Bian, Dong; Zhou, Xiaochen; Liu, Jianing; Li, Wenting; Shen, Danni; Zheng, Yufeng; Gu, Wenda; Jiang, Jingjun; Li, Mei; Chu, Xiao

DOI

[10.1016/j.actbio.2021.01.031](https://doi.org/10.1016/j.actbio.2021.01.031)

Publication date

2021

Document Version

Accepted author manuscript

Published in

Acta Biomaterialia

Citation (APA)

Bian, D., Zhou, X., Liu, J., Li, W., Shen, D., Zheng, Y., Gu, W., Jiang, J., Li, M., Chu, X., Ma, L., Wang, X., Zhang, Y., Leeflang, S., & Zhou, J. (2021). Degradation behaviors and in-vivo biocompatibility of a rare earth- and aluminum-free magnesium-based stent. *Acta Biomaterialia*, 124, 382-397. <https://doi.org/10.1016/j.actbio.2021.01.031>

Important note

To cite this publication, please use the final published version (if applicable). Please check the document version above.

Copyright

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.


Takedown policy

Please contact us and provide details if you believe this document breaches copyrights. We will remove access to the work immediately and investigate your claim.


Statement of significance

In the present study, a Mg-8.5Li (wt.%) alloy (RE- and Al-free) with an excellent ductility was processed into mini-tubes, and further fabricated into finished stent through laser cutting and electropolishing. In-vitro and in-vivo degradation behaviors and biocompatibility of the stent were evaluated by performing implantation in iliac artery of minipigs. The stent exhibited a decent degradation rate (0.15 mm/y) in vitro, but divergent result (> 0.6 mm/y) was found in vivo. The stent did not induce possible thrombus, and it was tolerable by surrounding tissues. Moreover, fast endothelial coverage in 1 month was achieved. Apparently, Mg-Li based biodegradable stent shows virtue from the criteria of elemental biocompatibility.

In-vitro



In-vivo



Degradation behaviors and *in-vivo* biocompatibility of a rare earth- and aluminum-free magnesium-based stent

Dong Bian ^a, Xiaochen Zhou ^b, Jianing Liu ^c, Wenting Li ^b, Danni Shen ^b, Yufeng Zheng ^{a, b, c, *}, Wenda Gu ^d, Jingjun Jiang ^{e, **}, Mei Li ^a, Xiao Chu ^a, Limin Ma ^a, Xiaolan Wang ^a, Yu Zhang ^a, Sander Leeftlang ^f, Jie Zhou ^{f, ***}

^a Department of Orthopedics, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China

^b Department of Materials Science and Engineering, College of Engineering, Peking University, Beijing, 100871, China

^c Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China

^d Department of Cardiac Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China

^e Department of Vascular Surgery, Peking University People's Hospital, Beijing, 100044, China

^f Department of Biomechanical Engineering, Delft University of Technology, Mekelweg 2, 2628 CD Delft, The Netherlands

* Corresponding author (Biomaterials). Department of Orthopedics, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China

** Co-corresponding author (Vascular Surgery). Department of Vascular Surgery, Peking University People's Hospital, Beijing, 100044, China

*** Co-corresponding author (Mg alloys). Department of Biomechanical Engineering,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

Biodegradable stents can provide scaffolding and anti-restenosis benefits in the short term and then gradually disappear over time to free the vessel, among which the Mg-based biodegradable stents (BDS) have been prosperously developed. In the present study, a Mg-8.5Li (wt.%) alloy (RE- and Al-free) with an excellent ductility was processed into mini-tubes, and further fabricated into finished stent through laser cutting and electropolishing. *In-vitro* degradation test was performed to evaluate the durability of this stent before and after balloon dilation. The influence of plastic deformation and residual stress (derived from the dilation process) on the degradation was checked with the assistance of finite element analysis. In addition, *in-vivo* degradation behaviors and biocompatibility of the stent were evaluated by performing implantation in iliac artery of minipigs. The balloon dilation process did not lead to deteriorated degradation, and this stent exhibited a decent degradation rate (0.15 mm/y) *in vitro*, but divergent result (> 0.6 mm/y) was found *in vivo*. The stent was almost completely degraded in 3 months, revealing an insufficient scaffolding time. Meanwhile, it did not induce possible thrombus, and it was tolerable by surrounding tissues. Besides, fast endothelial coverage in 1 month was achieved. In the end, the feasibility of this stent for treatment of benign vascular stenosis was generally discussed, and perspectives on future improvement of Mg-Li-based stents were proposed.

Keywords: biodegradable stent; Mg-Li alloy; degradation behavior; biocompatibility; iliac artery

1. Introduction

Since the first implantation of a coronary artery stent (bare metallic stent) in 1986 [1, 2], stent has become a dominant medical apparatus in the treatment of vascular stenosis [3, 4]. Up to now, the stent has experienced mainly three generations of innovation: bare metallic stent (BMS), drug-eluting stent (DES) and biodegradable stent (BDS) [5-7]. The restenosis rate has been well controlled ($< 5\%$) with current DESs [8, 9]. Nonetheless, complications such as risks of late stent thrombosis and impaired endothelial function still remained a concern as the lifelong existing of DES [10-14]. There are few reasons for the permanent remaining of the stent when remodeling of the stented vessel is completed [15]. Spontaneously, BDS seems to be the next generation and the ideal stent in the treatment of vascular stenosis.

Lately, magnesium-based (Mg-based) stents have attracted great attention as a revolutionized generation of BDS [6, 16]. In 2016, the Mg-based drug-eluting stent Magmaris (BIOTRONIK, Germany) received the CE mark approval [17, 18]. This new type of metallic BDS is expected to provide a temporary opening to a narrowed arterial vessel until the vessel remodeling is done, and to disappear progressively thereafter [19]. It opens a new horizon in the development of metallic BDSs, and also in the treatment of narrowed vessels. The promising results with good clinical and safety outcomes up to 3 years' follow-up support the use of Magmaris in simple coronary artery disease [20].

Owing to the unique biodegradability and excellent biocompatibility of Mg [21, 22], concerns with traditional BMSs or DESs, such as late thrombosis, long-term endothelial dysfunction, permanent physical irritation, chronic inflammatory local reactions, restricted vasoreactivity, etc., could possibly be avoided in Mg-based BDSs. Blood

vessels are set free from the metallic cage after full degradation of Mg-based BDSs [23].

This is particularly important in pediatrics as blood vessels of children and adolescents are immature, and they continue to grow. In addition, full degradation makes the restenting possible, and it also ameliorates the vessel wall quality. Due to the metallic nature, mechanical properties (radial strength, deformability, deliverability, etc.) of Mg-based BDSs are superior to their polymeric competitors. The body's ability to quickly resorb Mg leads to a faster and therefore more desirable resorption time than the polymer-based BDSs. Mg-based BDSs could emerge as a strong alternative to currently available polymeric BDSs.

In the past decades, some magnesium alloys have been developed as potential BDS materials, but only limited ones were fabricated into stents and performed animal trials, which include WE43 [24], AE21 [25], AZ31B [26], AZ91 [27], Mg-Nd-Zn-Zr [28], etc.

Among them, only the WE43-based one entered the clinical trial and finally received CE mark approval [20]. The vast majority of those alloys were aluminum (Al) containing or rare earth (RE) containing alloys. However, Al in biomedical applications is discouraged because of its possible toxicity [29]. Rare earth elements are not essential to human, and the long-term effect of RE on blood vessels needs further research [30, 31]. From the perspective of biological safety, the ideal alloying elements in Mg-based BDSs should be those which are essential to or naturally presented in human body [16].

Lithium (Li) is naturally presented in human body, and it is a possibly essential element to human health. Lithium salts have been used in the treatment of bipolar disorder for a long time [16, 32]. It is one of the two known elements (the other one is rare earth element scandium) which can change the hexagonal close-packed structure (hcp) of magnesium into body-centered cubic type (bcc), in this way improving ductility [33].

Just in time, good deformability is crucial for balloon expandable stent. So, Li is a

1 proper alloying element for magnesium alloys developed for BDSs. The good
2 biocompatibility of Mg-Li based alloys have already been proved in bones [34, 35].
3
4 However, no intravascular implantation of the Mg-Li alloy system has been reported
5
6
7 yet.

8
9 In our previous study [36], a Mg-8.5Li (wt.%) alloy composed of duplex $\alpha+\beta$ phases
10
11 was found to exhibit an excellent ductility ($> 40\%$), and this was particularly attractive
12
13 for radially expandable stent applications. Cytotoxicity tests confirmed that the Mg-
14
15 8.5Li alloy was compatible with human umbilical vein endothelial cells (ECV304),
16
17 while it significantly inhibited the proliferation of rodent vascular smooth muscle cells
18
19 (VSMC). This property might be favorable for promoting endothelialization and
20
21 inhibiting excessive VSMC hyperplasia.
22
23
24

25
26
27 Based on the previous results, the Mg-8.5Li alloy was processed into mini-tube, and
28
29 further fabricated into finished stent through laser cutting, acid pickling and
30
31 electropolishing, respectively. The structural integrity of the Mg-8.5Li stent after
32
33 balloon dilation was simulated through finite element analysis (FEA), and was also
34
35 verified through experimental observation. The *in-vitro* degradation behaviors before
36
37 and after balloon dilation were compared. Furthermore, the stent was deployed into
38
39 iliac artery in minipigs, and *in-vivo* performances were evaluated through micro-CT
40
41 scanning and histopathological examination. The feasibility of this stent to be used in
42
43 stenosed vessels was generally discussed. In the end, outlooks on the future
44
45 development of Mg-Li alloy based BDSs were proposed.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

2. Material and methods

2.1 Preparation of Mg-Li mini-tube and stent fabrication

The preparation of Mg-Li mini-tubes was performed in Delft University of Technology. A binary Mg-8.5Li alloy was supplied in as-cast form and was machined into extrusion billets with a diameter of 48 mm and a length of 200 mm. The Li content of the Mg-8.5Li billets, determined by using inductively coupled plasma optical emission spectrometry (ICP-OES, Prodigy 7, Leeman), was 8.48 wt.%. Those billets were preheated at 250 °C for 1 h, and then extruded at a reduction ratio of 20 and at a ram speed of 1 mm/s into bars with a diameter of 11.2 mm by using a 250 MT direct extrusion press. The extruded bars were machined into hollow billets with an outside diameter (OD) of 11 mm and a length of 26 mm. Then, they were indirectly extruded at 250 °C into mini-tubes with an OD of 3.2 mm, an insider diameter (ID) of 2.5 mm. Mg-Li stents were laser cut from those mini-tubes, and followed by acid pickling and electropolishing in Jiangyin Fasten-PLT Materials Science Co. Ltd. Pattern design of the stent was illustrated in Figure 1 (a). The stent for animal test was pre-mounted on a self-designed delivery balloon-catheter system, individually encapsulated, and sterilized under Co60 radiation before use.

2.2 Finite element analysis (FEA) of the stent

All the material parameters of the stent were obtained through experimental measurement. Figure 1 (c) displays the true stress-strain curve of the extruded Mg-8.5Li alloy. A homogeneous, isotropic, elasto-plastic material model was used. The 2D geometry model of the stent was created in SolidWorks 2014, as shown in Figure 1 (a). Then it was imported into Pro/E 5.0 to form the 3D model. The mesh generation was carried out in HyperMesh 12.0. The mesh density was studied, and a proper mesh

1 density was used in all the simulations in this work. Abaqus 2016 was used to run the
2 simulations. The FEA model was composed of two parts, i.e. a Mg-8.5Li stent and one
3 cylinder, as depicted in Figure 1 (b). The length of the cylinder is slightly longer than
4 that of the stent. After the stent was dilated/expanded to a certain size by means of
5 expanding the inner cylinder, it recoiled after removing the cylinder. The mirror
6 symmetry along the generatrix allows to simulate only half of the stent in order to
7 reduce the model size. A static analysis was performed with nonlinear geometry option
8 to better simulate the dilation and recoil processes. All the contact frictions were
9 ignored in the analysis for simplicity.

10 In these simulations, cylindrical coordinates were used. A cylinder was introduced to
11 control the dilation and recoil processes. The stent with the element type of C3D8R and
12 the cylinder with the element type of SFM3D4R were coaxial. For the half stent, the
13 axial degree of freedom was fixed at the open ends, and the circumferential degree of
14 freedom was fixed at one node to prevent the rigid body rotation. For the cylinder, both
15 circumferential and axial degrees of freedom are fixed. A radial displacement was
16 applied to the nodes of the cylinder to increase the inner radius to 1.75mm. Then, a -
17 0.35mm radial displacement was applied to the nodes of the cylinder to let the stent
18 gradually recoil. The stress and strain distributions on the stent during dilation and
19 recoil were analyzed.

20 ***2.3 In-vitro degradation characterization***

21 Eight stents were used for *in-vitro* degradation test, and four of them were balloon
22 dilated by using a balloon-catheter system ($\Phi 3.5 \times 20$ mm, Boston Scientific) at the
23 nominal pressure (NP, 8 atm) for 30 s. The surface integrity of the dilated stent was
24 examined under a scanning electron microscope (SEM, HITACHI S-4800, Japan),

1 equipped with an energy dispersive spectrometer (EDS). Immersion test was carried
2 out in Hank's solution (H1025, Solarbio) at 37 ± 0.5 °C with an exposure ratio of 20
3 mL/cm², according to ASTM-G31-72 [37]. During immersion, pH value of the Hank's
4 solution was monitored by using a pH meter (PB-10, Sartorius), with normal Hank's
5 solution as control. Concentrations of Mg, Li, Ca and P in the solution after immersion
6 were measured by ICP-OES (iCAP 6000, Thermo). The macro-morphology of the stent
7 after immersion was captured under a digital camera (Canon EOS 70D, Japan). The
8 surface was characterized by a Fourier transform infrared spectrometer (FTIR, Nicolet
9 iS 50, Thermo Scientific) and an imaging X-ray photoelectron spectrometer (XPS, Axis
10 Ultra, Kratos Analytical Ltd.). The FTIR spectrum was recorded over a range of 4000-
11 500 cm⁻¹ to identify functional groups in the sample surface. High resolution narrow
12 scanning of XPS was performed to determine the binding states of Mg 2p, O 1s, Ca 2p,
13 P 2p, C 1s, and Na 1s, by using Al K α radiation. Constituent phases in the degradation
14 product layer were identified by using an X-ray diffractometer (XRD, X'Pert Pro MPD).
15 Considering the small and irregular testing area on the stent, XRD test was performed
16 by using a Mono-Capillary PreFix Module operating at 45 kV and 40 mA with Cu K α
17 radiation, at a step size of 0.017° over a range of 10-90°. The structural integrity of
18 stents was examined under a micro-CT scanner (Latheta LCT 200, Hitachi-Aloka) at a
19 spatial resolution of 24 μ m. The 3D reconstruction was performed in Amira software
20 (Amira 6.0.1, Visage Imaging). One unexpanded stent along with an expanded stent
21 was embedded in cold mounting resin (BUBBLEFREE, TRUER) for cross-section
22 analysis. Samples were also observed under SEM before and after removing the
23 degradation products in chromic acid (200 g CrO₃ in 1000 mL H₂O), according to
24 ASTM-G1-90 [38]. The degradation rate was calculated according to the following
25 equation, $CR = 3.65\Delta W/\rho$ [39], where ΔW is the metal weight loss rate (mg/cm²/d) and
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

ρ is the metal density (g/cm^3).

2.4 In-vivo degradation and biocompatibility

2.4.1 Animal model and surgery

Animals were supplied by Beijing Ke Xing Experimental Animal Cultivation Center (animal use permit No.: SCXK (jing) 2012-0005). Six laboratory minipigs were fed with aspirin 3 days before operation at a dosage of 100 mg/d. The surgery was performed under general anesthesia by intravenous injection of 2% pentobarbital at the dosage of 30 mg/kg. Animals were placed abdomen-up and limbs fixed. Bilateral iliac arteries were isolated after opening the abdomen. Lumen diameter was measured through ultrasonography (GE Logic E), and it was in the range of 3.0-3.3 mm. A sheath (6Fr, TERUM0) was punched into the artery along the blood descending direction. After administration of unfractionated heparin through peripheral vein (systemic anticoagulation, 1 mg/kg), a Mg-8.5Li stent was delivered into the iliac artery (either left or right) and balloon dilated at 8 atm (NP, a nominal diameter of 3.5 mm) for 30 s to deploy the stent, under the guidance of a guide wire (0.014 inch). The contralateral iliac artery without implantation was set as normal control. Position of the stent was marked by two stitches at the adjacent tissues on both ends of the stented section (a total marked vessel length of 5 cm), in much convenience for recycling samples. The artery patency was confirmed by intraoperative ultrasonography. Finally, the wound was well sutured (7-0 Prolene) and patched with aseptic dressing. Antiplatelet therapy was performed by giving 100 mg aspirin daily after the implantation. Two animals were sacrificed at 1, 2 and 3 months post-operation, respectively. The patency of the iliac artery was confirmed through ultrasonography during the dissection. The stented iliac artery and the normal iliac artery were both retrieved for follow-up analysis. The

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
anesthetic, surgical and post-operative care protocols were examined by and fulfilled the requirements of the Ethics Committee of Peking University People's Hospital.

2.4.2 *In-vivo degradation and histological evaluation*

Retrieved iliac arteries were immediately examined under a micro-CT scanner (Skyscan1076, Bruker) at a spatial resolution of 9 μm . The 3D reconstruction of the remaining stent was performed in Mimics software (Mimics 10.01, Materialise Mimics[®]). Pathological examination of the stented vessel and the normal vessel was performed by using conventional paraffin-embedded sectioning and staining with hematoxylin-eosin (H&E, Guge Biological Technology Co., Ltd.). Specifically, one sample at 1 month was longitudinally cut open and separated into two parts. One part was fixed in 2.5% glutaraldehyde solutions followed by dehydration in gradient ethanol/distilled water mixtures (50%, 60%, 70%, 80%, 90% and 100%, 10 min for each). The endothelialization condition of the stent was observed under SEM after spraying with Au. For the other part, the remaining stent was directly extracted from the vessel tissues and examined under SEM.

2.5 *Statistical analysis*

Data in this work were expressed as means \pm standard deviation. Statistical analysis was performed with SPSS 18.0 software (SPSS Inc., Chicago, USA). Differences between groups were analyzed by using one-way analysis of variance (ANOVA) followed by Tukey test. The statistical significance was defined as * $p < 0.05$.

3. Results

3.1 FEA result

Figure 2 shows the distribution of principal strain and stress on the stent after it was dilated and naturally recoiled. The maximum principal strain after dilation was mainly concentrated at the crown (typical position of each part on the stent is indicated in Figure 1 (a)), with tension strain at the inner surface and compression strain at the other side, i.e. the outer surface of the crown. The maximum principal strain after dilation (similar to balloon dilation to 3.5 mm) was 3.12%, which was well below the fracture limit of Mg-8.5Li alloy ($> 40\%$). The bridge between two crowns alleviated the principal strains at both neighboring crowns, as indicated by blue arrows in Figure 2 (b) (compared with the red arrow indicated sites). The distribution of the maximum principal stress during dilation was similar to that of the maximum principal strain, all concentrated at the crowns, as marked by red arrows in Figure 2 (c). A maximum principal stress of 134.7 MPa and a radial recoil of 3.3% were found after dilation. The distribution of residual stress after unloading was presented in the right side of Figure 2 (c). A maximum residual tension stress of 60.8 MPa appeared near the outside surface of the crown (upper site, the orientation is illustrated in Figure 2 (a)) while the maximum residual compression stress was found near the internal surface at the crown, as shown in the enlarged images. Generally, the balloon dilation process would not induce any damage to the stent, judging from the FEA results.

3.2 *In-vitro degradation behavior*

Figure 3 shows the macroscopic morphologies of the stent before and after immersion under an optical camera and under radioscopy. The original stent owned a smooth surface and was shining with metallic luster. Balloon dilation (8 atm, expansion to $\Phi 3.5$ mm) did not induce any visible fractures or defects on the stent. The dogboning effect during dilation was not obvious. The deformation of Mg-8.5Li stent was generally uniform in both axial and radial directions. After immersion for 7 days, the stent surface became pale, and a greyish degradation product layer could be observed. A fracture occurred casually at a strut section on one of the unexpanded stents, as indicated by red arrows in Figure 3 (a). The stent integrity after immersion was examined under X-ray, as depicted in Figure 3 (b). Generally, the structural integrity was mainly maintained after immersion. However, at limited sites, low-density areas were found under X-ray, showing the appearance of localized degradation. At those sites, the remaining stent struts became much thinner, as revealed by the micro-CT results. The localized degradation was suspected to be closely related to the componential (impurities) and microstructural heterogeneity.

Figure 4 shows the microscopic morphologies of the stent before and after removing the degradation products. Surface details could be revealed under SEM. Before immersion, the original stent exhibited a smooth surface without sharp edges. After balloon dilation, the stent surface kept intact without any fractures/cracks, indicating the good deformability. After immersion, the strut surface was covered with a degradation product layer with some white deposits on top of it. This layer was mainly composed of Mg, O, Ca, P, C and Na, as revealed by EDS analysis. Degradation of the stent was generally uniform. However, a few localized degradation sites were also found on the stents whether they were dilated or not, as marked by red arrows.

1 Degradation products accumulated on those sites and they were in a loose condition.
2
3 The sites where localized degradation happened seemed to be irregular and random, not
4
5 appearing at a specific site. After removing the degradation products, the actual
6
7 morphology of the strut was exposed. Except for the limited local degradation sites, the
8
9 stent exhibited a generally uniform degradation morphology. At severely localized
10
11 degradation sites, deep holes were revealed. The degradation seemed to be
12
13 preferentially occurred at specific directions, maybe along specific lattice planes, as
14
15 revealed in the inserts in Figure 4 (b). On the microscopic level, the stent is susceptible
16
17 to pitting, as shown in the enlarged SEM images. Clear and intact grain boundaries
18
19 could still be observed after removing the degradation products, as shown in inserts of
20
21 Figure 4 (b). The degradation at the grain boundaries was not severe than the
22
23 degradation in the interior of the grains, suggesting that grain boundaries were not the
24
25 vulnerable sites during degradation.
26
27
28
29
30

31 Figure 5 (a) displays the cross-sectional morphologies of the stents and corresponding
32
33 EDS element mapping (red: Mg, green: O, blue: Ca, cyan: P, purple: C). The stent strut
34
35 was covered by a thin degradation product layer. In areas where degradation was more
36
37 severe, this layer was much thicker. Ca and P were found to be enriched in the surface
38
39 of the degradation products, indicating Ca/P deposits on the degradation product layer.
40
41 Figure 5 (b) and (c) shows the pH variation during a 7-day-immersion and element
42
43 concentrations after immersion, respectively. At the beginning, there was a certain pH
44
45 increase of the Hank's solution, suggesting a fast stent degradation during this period.
46
47 Afterwards, the pH value increased slowly and finally reached a relatively stable value
48
49 around 8.8 in the experimental groups. During the whole immersion period, pH value
50
51 of the dilated stent group was always slightly higher than that of the unexpanded group
52
53 (stent without dilation). However, there was no significant difference. There was almost
54
55
56
57
58
59
60

1 no difference in the Mg and Li concentrations between those two groups, as shown in
2 Figure 5 (c). Compared to the blank control group, reduced Ca and P were detected
3 after immersion in the experimental groups with Mg-8.5Li stents. Deposition of Ca and
4 P on the degraded stent should be responsible for their decrease in the medium.
5 Degradation rates (calculated from weight loss) of the stents before dilation and after
6 dilation were 0.113 ± 0.028 mm/y and 0.145 ± 0.031 mm/y, respectively. A little higher
7 degradation rate was found in the balloon dilated group. However, no significant
8 difference was detected.

9 Figure 6 shows the XPS, FTIR and XRD results of the Mg-8.5Li stent after immersion.
10 XPS result revealed that elements including Mg, O, Ca, P, C and minor Na were
11 detected on the sample surface. High resolution narrow scanning confirmed the possible
12 presence of calcium phosphate or hydroxyapatite on the surface, as indicated by the Ca
13 2p peak at 350.90 eV, along with P 2p peak at 133.36 eV and O 1s peak at 531.17 eV
14 [40, 41]. The O 1s peak at 532.65 eV and C 1s peak at 284.87 eV could be attributed to
15 the CO_3^{2-} [40]. The Na 1s peak at 1071.82 eV is assigned to a small amount of NaCl,
16 which precipitated from the Hank's solution. FTIR spectrum indicated the presence of
17 possible functional groups including H_2O , OH^- , CO_3^- , PO_4^{3-} and possible $\text{H}_2\text{PO}_4^{2-}$ [42,
18 43], as shown in Figure 6 (b). The mainly crystalline degradation products could be
19 directly identified through XRD analysis, and they were mainly composed of $\text{Mg}(\text{OH})_2$,
20 $\text{MgCO}_3\cdot 2\text{H}_2\text{O}$ and $\text{CaMg}_5(\text{CO}_3)(\text{PO}_4)_4(\text{OH})$, as depicted in Figure 6 (c). Weak peaks
21 from the β -Li phase could also be detected through XRD analysis.

22 ***3.3 In-vivo degradation and biocompatibility***

23 Figure 7 (a) shows the stent implantation process and retrieval of the target vessels.
24 After the laparotomy, patency of the stented vessels was verified through ultrasonic
25

1 examination, and all the implanted vessels showed unobstructed blood flow. There was
2 no noticeable difference between the stented vessels and the normal control vessels
3 through gross examination. The stent could be felt through gentle touch along the
4 stented vessels after 1 month. In the next month, the stent could be barely felt, implying
5 serious degradation by this time (2-month post-operation). The stented vessels
6 exhibited good vascular adaptability as they could be easily curled and twisted without
7 sensation of foreign matter at month 3. No thrombosis or blood clotting was found in
8 the stented section or far from the stent through general observation.

9 Figure 7 (b) displays the 3D reconstruction of the remaining stent in the iliac arteries.
10 The major part of the stent still existed, and the remaining stent kept as a whole after 1
11 month. Even though some struts fractured, the structure and shape of the stent could
12 still be distinguished. The remaining part maintained most of its structural integrity.
13 After 2 months, the stent was seriously degraded as the remaining part has fractured
14 into small pieces, and the stent units were no longer interconnected. The stent strut has
15 become much thinner and rougher compared to that at 1 month. After 3 months, only
16 some residual particles in limited size and limited amount could be detected. No
17 substances with density higher than the vessel wall could be found in the normal control
18 vessels. Generally, the Mg-8.5Li stent exhibited an over-quick degradation *in vivo*, and
19 it was almost fully degraded after 3 months (*in-vivo* degradation rate > 0.6 mm/y).

20 Histological images of the stented iliac arteries at different time points were listed in
21 Figure 7 (c), with normal iliac artery as control. The voids where the stent struts
22 previously occupied before slicing and staining could be clearly seen, as indicated by
23 black triangles. Fast endothelial coverage in the first month could be found as the struts
24 were covered by a monolayer of cells. Due to the mechanical mismatch between the
25 stent platform and paraffin permeated tissues, some of the tissues were torn away from
26

1 their original positions during slicing procedure, as indicated by the long red arrow in
2 Figure 7 (c). Only limited stent remnants were observed after 2 months, and the
3
4 surrounding tissues penetrated into the spaces where the stent struts held before. At
5
6 month 2, the stent struts were embedded in the middle layer of the vascular membrane,
7
8 well beneath the intima. A certain degree of inflammatory response was observed. The
9
10 adjacent tissues surrounding the struts appeared to be a little bit loose and irregular at
11
12 month 2, when compared to the normal control or tissues at month 3. It was probably
13
14 caused by the fast stent degradation and the by-products (hydrogen, degradation
15
16 products) which were generated during stent degradation.
17
18
19
20

21 During stent degradation, some debris or degradation products could also be observed
22
23 in the tissues adjacent to the stent struts, as illustrated by red arrows in Figure 7 (c).
24
25 After implantation for 3 months, no obvious stent debris or residues could be found
26
27 through histological examination, implying that the Mg-8.5Li stent could be fully
28
29 absorbed soon after. The tiny particles observed under micro-CT at month 3 (Figure 7
30
31 (b)) were not easily found in the histological images (Figure 7 (c)), since they were in
32
33 limited size and were not easy to be exactly sliced. The recovered artery tissues at month
34
35 3 exhibited no microscopic difference to the normal iliac artery. However, unfortunately,
36
37 the intima-medial thickness was thicker than the normal control.
38
39
40
41
42

43 Figure 8 (a) depicts the endothelial coverage status of the Mg-8.5Li stent after 1 month.
44
45 The corresponding morphology of the stent after directly extracted from the vascular
46
47 tissues was shown in Figure 8 (b). Endothelial cells could migrate across the
48
49 protuberant struts, and then covered the whole stent. After 1 month, a monolayer of
50
51 fusiform endothelial cells was formed on the stent struts, showing a fast
52
53 endothelialization, consistent with the histological results at 1 month. The fast
54
55 endothelialization, consistent with the histological results at 1 month. The fast
56
57 endothelialization is favorable for lowering possible adverse reactions, such as
58
59
60
61
62
63
64
65

1 restenosis and thrombus. As for the stent itself, a degradation product layer was formed.
2 This layer was ruptured and peeled off due to dissociation (separation from the tissue)
3 and dehydration. Elements of Mg, O, Ca, P, C, Na were detected in the degradation
4 product layer through EDS characterization. In the peeling-off areas, such as area B,
5 contents of Ca and P were less than those in the intact areas (area A). Meanwhile, higher
6 contents of O and C were found in peeling-off areas. This suggested that Ca and P
7 tended to be enriched on the surface of the degradation product layer. Similar results
8 were also observed during the *in-vitro* degradation of Mg-8.5Li stent. Elements in the
9 degradation products were similar both *in vitro* and *in vivo*, so as the XPS results. So,
10 the major constituent phases in the degradation product layer should also be alike.
11
12
13
14
15
16
17
18
19
20
21
22
23
24

25 **4. Discussion**

26 ***4.1 The feasibility of Mg-8.5Li alloy stent for treatment of benign luminal diseases***

27 One of the most crucial problems for Mg-based BDSs is that they degraded too fast,
28 and premature loss of radial force before vascular remodeling might lead to restenosis.
29 Erinc et al. [44] proposed that degradation rate of magnesium alloys should be lower
30 than 0.5 mm/y to satisfy the requirement for BDS. According to recent research, Mg-
31 based BDS should maintain mechanical support for 3-4 months to help the vessel
32 remodeling [16, 45]. Therefore, for a BDS with a strut thickness of 150 μm , the
33 degradation rate should be lower than 0.23 mm/y. The *in-vitro* degradation rate of our
34 Mg-Li stent was encouraging as it was as low as < 0.15 mm/y (0.113 ± 0.028 mm/y
35 before dilation and 0.145 ± 0.031 mm/y after dilation, no statistical difference). The
36 balloon dilation process did not make much difference to the degradation behaviors.
37 Plastic deformation and residual stress resulted from the dilation process did not lead
38 to deteriorated degradation, as depicted in Figure 4. This is what we expected as the
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 stent degraded uniformly, and avoided prematurely partial collapse.

2
3 However, the Mg-8.5Li stent has demonstrated swift degradation within 3 months in
4 the iliac artery of minipigs. *In-vivo* degradation rate (> 0.6 mm/y) of this stent was
5 significantly higher than the *in-vitro* result (0.145 ± 0.031 mm/y). The disparity could be
6 ascribed to the big differences between *in-vitro* and *in-vivo* environments (huge gaps in
7 chemical, mechanical, fluidic, cellular and tissular aspects, etc.). Such rapid
8 degradation may result in early recoil because of the lack of radial force exerted by the
9 stent at this early stage of healing (showing insufficient mechanical support at 1 month).
10
11 The short scaffolding duration is insufficient for coronary or peripheral applications.
12
13 Nonetheless, the Mg-8.5Li stent still could be tolerated by surrounding tissues even
14 under this intense degradation condition. In addition, only moderate tissue hyperplasia
15 occurred, and that was not such bad, as already shown in Figure 7. Basically,
16 components and degradation products of the Mg-8.5Li stent were tolerable in iliac
17 artery of minipigs. Tissue responses might be further improved if the degradation was
18 well controlled.

36 37 **4.2 Comparison with other Mg-based BDSs**

38
39 For in-depth understanding of the Mg-8.5Li stent performance, key performances
40 (mainly focusing on the degradation behaviors and biocompatibility) of previously
41 reported Mg-based BDSs were listed in Table 1 for comparison. A vast majority of
42 those BDSs were fabricated from the AZ-based (Al-containing) or RE-containing alloy
43 series. Except for one WE43 stent, which was reported to be associated with occluded
44 and thrombosed artery (suspected to be related to rare-earth elements) according to the
45 research of Bornapour et al.[46], the remaining Mg-based BDSs exhibited proper or
46 good biocompatibility. The strut thickness of currently developed Mg-based BDSs was
47 in the range of 80-250 μm , usually to be 150 μm . *In-vitro* degradation rate of our Mg-
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

8.5Li stent was smaller than that of other bare Mg-based BDSs, and the *in-vivo* degradation rate was comparable to its counterparts without coatings. Apparently, Mg-Li based BDS shows virtue from the criteria of elemental biocompatibility.

4.3 Perspectives on future development of Mg-Li alloy based BDS

4.3.1 Stronger platform material and thinner stent strut

The strut thickness is a crucial parameter for both permanent stents and biodegradable stents, as it is associated with local flow pattern and endothelialization, which have been shown to influence local inflammation, rate of restenosis, and thrombogenicity [47]. Thinner strut leads to better clinical performances as proved through the evolution of DESs [48, 49]. The strut thickness of Mg-based BDSs is substantially larger than that in currently available durable DESs. The next generation (DREAMS 3G) of Magmaris (also known as DREAMS 2G, a strut thickness of 150 μm) is being developed with thinner strut thickness (99-150 μm) and prolonged scaffolding time. A robust platform material favors for the design of thinner strut, without compensation of radial strength. Alloying with Li provides with excellent ductility, the basis for balloon expandable BDS. However, the strength of binary Mg-Li alloys is generally less than satisfactory. Another supplementary alloying element can be helpful in enhancing mechanical strength, and Zn might be a proper choice herein [50].

4.3.2 Deal with the fast degradation of Mg-Li BDS

Figure 9 compared the *in-vitro* degradation rates and *in-vivo* full degradation periods of various Mg-based BDSs with or without protective coatings. Generally, excessive degradation is a prevalent problem faced by bare Mg-based BDSs, and the degradation duration ranges from several days to a few months among different BDS platform

1 materials [6, 27, 51]. Surface coating is an effective way which can substantially
2 improve corrosion resistance [52]. It helps maintain the mechanical integrity for a
3 longer time, and improves Mg-based BDS performance. Even for the precursor of
4 Magmaris, i.e. the first generation of absorbable metallic stent AMS in Biotronik, the
5 durability was only 3-4 months in porcine coronaries or in human coronary arteries [51,
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

durability was only 3-4 months in porcine coronaries or in human coronary arteries [51, 53]. Polymeric coating was adopted on the next two generations (DREAMS 1G and DREAM 2G), along with refined platform material, the scaffolding time was prolonged to 3 months, and the whole degradation period was improved up to 12 months [20]. The clinical experience with DESs by using limus-type (sirolimus, everolimus) anti-proliferative drugs to lower hyperplasia should also be considered in R&D of Mg-based BDSs.

As we mentioned before, dilation/expansion of Mg-based BDSs is through plastic deformation. The maximum strain during stent deployment should not exceed the fracture limit of the platform material. A certain extent of plastic deformation and residual stress have been shown to affect the degradation behavior [54, 55]. The maximum strain and maximum residual stress induced during the deployment process should be strictly controlled. Otherwise, severely localized degradation could happen at those sites, leading to non-uniform degradation and premature fracture. Proper pattern design and shape optimization through FEA method is practicable in improving the performance of Mg-based BDSs [56].

5. Conclusions

In the present study, the feasibility of a novel Mg-8.5Li stent to be used in the treatment of stenosed vessels was preliminarily evaluated, mainly focusing on the degradation behaviors and *in-vivo* biocompatibility. Plastic deformation and residual stress derived

1 from the balloon dilation process did not lead to deteriorated degradation. This stent
2 exhibited a decent degradation rate of < 0.15 mm/y *in vitro*, showing possibility to
3 maintain for a long scaffolding period *in vivo*. However, its implantation in iliac artery
4 of minipigs revealed divergent results (degradation rate > 0.6 mm/y), showing an
5 insufficient scaffolding time. The basic thing, though, is that this stent did not induce
6 possible thrombus, and it was tolerable in surrounding arterial tissues. Besides, fast
7 endothelial coverage of the stent was achieved within 1 month even under this radical
8 degradation condition. The degradation needs to be well controlled to improve *in-vivo*
9 performance in future work.
10
11
12
13
14
15
16
17
18
19
20
21

22 **Acknowledgements**

23
24
25
26 This work was supported by the National Key R&D Program of China
27 (2016YFC1102400), National Natural Science Foundation of China (Grant No.
28 51871004), and NSFC/RGC Joint Research Scheme (Grant No. 51661165014).
29
30
31
32
33

34 **References**

- 35
36
37
38 [1] R.L. Mueller, T.A. Sanborn, The history of interventional cardiology: cardiac
39 catheterization, angioplasty, and related interventions, *Am. Heart J.* 129(1) (1995) 146-
40 172.
41
42
43
44 [2] U. Sigwart, J. Puel, V. Mirkovitch, F. Joffre, L. Kappenberger, Intravascular stents
45 to prevent occlusion and restenosis after transluminal angioplasty, *N. Engl. J. Med.*
46 316(12) (1987) 701-706.
47
48
49
50 [3] J. Iqbal, J. Gunn, P.W. Serruys, Coronary stents: historical development, current
51 status and future directions, *Brit. Med. Bull.* 106(1) (2013) 193-211.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1 [4] P.W. Serruys, M.J.B. Kutryk, A.T.L. Ong, Coronary-artery stents, *N. Engl. J. Med.*
2
3 354(5) (2006) 483-495.
4
5
6 [5] A. Purnama, H. Hermawan, D. Mantovani, Biodegradable metal stents: a focused
7
8 review on materials and clinical studies, *J. Biomater. Tiss. Eng.* 4(11) (2014) 868-874.
9
10
11 [6] Y.Q. Zhu, K. Yang, R.Y. Cheng, Y. Xiang, T.W. Yuan, Y.S. Cheng, B. Sarmento,
12
13 W.G. Cui, The current status of biodegradable stent to treat benign luminal disease,
14
15 *Mater. Today* 20(9) (2017) 516-529.
16
17
18 [7] H.S. Han, S. Loffredo, I. Jun, J. Edwards, Y.C. Kim, H.K. Seok, F. Witte, D.
19
20 Mantovani, S. Glyn-Jones, Current status and outlook on the clinical translation of
21
22 biodegradable metals, *Mater. Today* 23 (2019) 57-71.
23
24
25
26 [8] N. Kukreja, Y. Onuma, J. Daemen, P.W. Serruys, The future of drug-eluting stents,
27
28 *Pharmacol. Res.* 57(3) (2008) 171-180.
29
30
31 [9] M.J. Eisenberg, K.J. Konnyu, Review of randomized clinical trials of drug-eluting
32
33 stents for the prevention of in-stent restenosis, *Am. J. Cardiol.* 98(3) (2006) 375-382.
34
35
36
37 [10] A.T.L. Ong, E.P. Mcfadden, E. Regar, P.P.T.D. Jaegere, R.T.V. Domburg, P.W.
38
39 Serruys, Late angiographic stent thrombosis (LAST) events with drug-eluting stents, *J.*
40
41 *Am. Coll. Cardiol.* 45(12) (2005) 2088-2092.
42
43
44
45 [11] A.A. Bavry, D.L. Bhatt, Appropriate use of drug-eluting stents: balancing the
46
47 reduction in restenosis with the concern of late thrombosis, *Lancet* 371(9630) (2008)
48
49 2134-2143.
50
51
52
53 [12] S.H. Hofma, V.D.G. Wj, B.M. van Dalen, P.A. Lemos, E.P. Mcfadden, G. Sianos,
54
55 J.M. Ligthart, E.D. Van, P.J. de Feyter, P.W. Serruys, Indication of long-term endothelial
56
57
58
59
60

1 dysfunction after sirolimus-eluting stent implantation, *Eur. Heart J.* 27(2) (2006) 166-
2
3 170.

4
5
6 [13] M. Togni, S. Windecker, R. Cocchia, P. Wenaweser, S. Cook, M. Billinger, B.
7
8 Meier, O.M. Hess, Sirolimus-eluting stents associated with paradoxical coronary
9
10 vasoconstriction, *J. Am. Coll. Cardiol.* 46(2) (2005) 231-236.

11
12
13 [14] A.V. Finn, M. Joner, G. Nakazawa, F. Kolodgie, J. Newell, M.C. John, H.K. Gold,
14
15 R. Virmani, Pathological correlates of late drug-eluting stent thrombosis: strut coverage
16
17 as a marker of endothelialization, *Circulation* 115(18) (2007) 2435-2441.

18
19
20 [15] G. Mani, M.D. Feldman, D. Patel, C.M. Agrawal, Coronary stents: a materials
21
22 perspective, *Biomaterials* 28(9) (2007) 1689-1710.

23
24
25 [16] Y.F. Zheng, X.N. Gu, F. Witte, Biodegradable metals, *Mat. Sci. Eng. R.* 77(0) (2014)
26
27 1-34.

28
29
30 [17] M. Haude, H. Ince, A. Abizaid, R. Toelg, P.A. Lemos, C. von Birgelen, E.H.
31
32 Christiansen, W. Wijns, F.J. Neumann, C. Kaiser, E. Eeckhout, S.T. Lim, J. Escaned,
33
34 H.M. Garcia-Garcia, R. Waksman, Safety and performance of the second-generation
35
36 drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions
37
38 (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-
39
40 in-man trial, *Lancet* 387(10013) (2016) 31-39.

41
42 [18] <http://www.magmaris.com/>. last accessed on September 17, 2020.

43
44 [19] H. Hermawan, D. Dubé, D. Mantovani, Developments in metallic biodegradable
45
46 stents, *Acta Biomater.* 6(5) (2010) 1693-1697.

47
48 [20] J. Bennett, Q.D. Hemptinne, K. McCutcheon, Magmaris resorbable magnesium
49
50

1 scaffold for the treatment of coronary heart disease: overview of its safety and efficacy,
2
3 Expert Rev. Med. Devic. 16(9) (2019) 757-769.
4

5
6 [21] J. Vormann, Magnesium: nutrition and metabolism, Mol. Aspects of Med. 24(1-3)
7
8 (2003) 27-37.
9

10
11 [22] F. Witte, Reprint of: the history of biodegradable magnesium implants: a review,
12
13 Acta Biomater. 23 (2015) S28-S40.
14

15
16 [23] Y. Onuma, T. Muramatsu, A. Kharlamov, P.W. Serruys, Freeing the vessel from
17
18 metallic cage: what can we achieve with bioresorbable vascular scaffolds?, Cardiovasc.
19
20 Interv. & Ther. 27(3) (2012) 141-154.
21

22
23 [24] R. Waksman, R. Pakala, P.K. Kuchulakanti, R. Baffour, D. Hellings, R. Seabron,
24
25 F.O. Tio, E. Wittchow, S. Hartwig, C. Harder, R. Rohde, B. Heublein, A. Andreae, K.-
26
27 H. Waldmann, A. Haverich, Safety and efficacy of bioabsorbable magnesium alloy
28
29 stents in porcine coronary arteries, Catheter. Cardio. Inte. 68(4) (2006) 607-617.
30
31

32
33 [25] B. Heublein, R. Rohde, V. Kaese, M. Niemeyer, W. Hartung, A. Haverich,
34
35 Biocorrosion of magnesium alloys: a new principle in cardiovascular implant
36
37 technology?, Heart 89(6) (2003) 651-656.
38
39

40
41 [26] H.W. Li, H.S. Zhong, K. Xu, K. Yang, J. Liu, B.C. Zhang, F. Zheng, Y.H. Xia, L.L.
42
43 Tan, D. Hong, Enhanced efficacy of sirolimus-eluting bioabsorbable magnesium alloy
44
45 stents in the prevention of restenosis, J. Endovasc. Ther. 18(3) (2011) 407-415.
46
47

48
49 [27] Y. Yue, L.L. Wang, N. Yang, J.L. Huang, L.C. Lei, H.M. Ye, L.H. Ren, S.X. Yang,
50
51 Effectiveness of biodegradable magnesium alloy stents in coronary artery and femoral
52
53 artery, J. Interv. Cardiol. 28(4) (2015) 358-364.
54
55
56
57
58
59

- 1 [28] Y.J. Shi, L. Zhang, J.H. Chen, J. Zhang, F. Yuan, L. Shen, C.X. Chen, J. Pei, Z.H.
2
3 Li, J.Y. Tan, G.Y. Yuan, In vitro and in vivo degradation of rapamycin-eluting Mg-Nd-
4
5 Zn-Zr alloy stents in porcine coronary arteries, *Mat. Sci. Eng. C.* 80 (2017) 1-6.
6
7
8
9 [29] P.C. Ferreira, K.A. Piai, A.M. Takayanagui, S.I. Segura-Muñoz, Aluminum as a
10
11 risk factor for Alzheimer's disease, *Rev. Latino-Am. Enfermagem* 16(1) (2008) 151-
12
13 157.
14
15
16
17 [30] F. Feyerabend, J. Fischer, J. Holtz, F. Witte, R. Willumeit, H. Drücker, C. Vogt, N.
18
19 Hort, Evaluation of short-term effects of rare earth and other elements used in
20
21 magnesium alloys on primary cells and cell lines, *Acta Biomater.* 6(5) (2010) 1834-
22
23 1842.
24
25
26
27 [31] A. Drynda, N. Deinet, N. Braun, M. Peuster, Rare earth metals used in
28
29 biodegradable magnesium-based stents do not interfere with proliferation of smooth
30
31 muscle cells but do induce the upregulation of inflammatory genes, *J. Biomed. Mater.*
32
33 *Res. A.* 91A(2) (2009) 360-369.
34
35
36
37 [32] A.M. Pérez-Granados, M.P. Vaquero, Silicon, aluminium, arsenic and lithium:
38
39 essentiality and human health implications, *J. Nutr. Health Aging* 6(2) (2002) 154-162.
40
41
42
43 [33] F.W. Bach, M. Schaper, C. Jaschik, Influence of lithium on hcp magnesium alloys,
44
45 *Mater. Sci. Forum* 419-422 (2003) 1037-1042.
46
47
48
49 [34] F. Witte, J. Fischer, J. Nellesen, C. Vogt, J. Vogt, T. Donath, F. Beckmann, In vivo
50
51 corrosion and corrosion protection of magnesium alloy LAE442, *Acta Biomater.* 6(5)
52
53 (2010) 1792-1799.
54
55
56
57 [35] D.D. Xia, Y. Liu, S.Y. Wang, R.C. Zeng, Y.S. Liu, Y.F. Zheng, Y.S. Zhou, In vitro
58
59

1 and in vivo investigation on biodegradable Mg-Li-Ca alloys for bone implant
2 application, *Sci. China Mater.* 62(2) (2019) 256-272.
3
4

5
6 [36] W.R. Zhou, Y.F. Zheng, M.A. Leeftang, J. Zhou, Mechanical property,
7 biocorrosion and in vitro biocompatibility evaluations of Mg-Li-(Al)-(RE) alloys for
8 future cardiovascular stent application, *Acta Biomater.* 9(10) (2013) 8488-8498.
9
10

11
12 [37] ASTM G31-72(2004), Standard Practice for Laboratory Immersion Corrosion
13 Testing of Metals, ASTM International, West Conshohocken, PA, 2004.
14
15

16
17 [38] ASTM G1-03(2017)e1, Standard Practice for Preparing, Cleaning, and Evaluating
18 Corrosion Test Specimens, ASTM International, West Conshohocken, PA, 2017
19
20

21
22 [39] Z.M. Shi, M. Liu, A. Atrens, Measurement of the corrosion rate of magnesium
23 alloys using Tafel extrapolation, *Corros. Sci.* 52(2) (2010) 579-588.
24
25

26
27 [40] T. Fu, J.T. Fan, Y.G. Shen, J.M. Sun, Hydrothermal calcification of alkali treated
28 titanium in CaHPO_4 solution, *Mater. Chem. Phys.* 189 (2017) 105-110.
29
30

31
32 [41] B. Demri, D. Muster, XPS study of some calcium compounds, *J. Mater. Process.*
33 *Technol.* 55(3-4) (1995) 311-314.
34
35

36
37 [42] H.R. Bakhsheshi-Rad, M.H. Idris, M.R. Abdul-Kadir, A. Ourdjini, M. Medraj, M.
38 Daroonparvar, E. Hamzah, Mechanical and bio-corrosion properties of quaternary Mg-
39 Ca-Mn-Zn alloys compared with binary Mg-Ca alloys, *Mater. Design* 53 (2014) 283-
40 292.
41
42

43
44 [43] P.K. Bowen, J. Drelich, J. Goldman, Magnesium in the murine artery: probing the
45 products of corrosion, *Acta Biomater.* 10(3) (2014) 1475-1483.
46
47

48
49 [44] M. Erinc, W.H. Sillekens, R.G.T.M. Mannens, R.J. Werkhoven, Applicability of
50
51

1 existing magnesium alloys as biomedical implant materials, *Magnesium Technology*
2
3 (2009) 209-214.
4

5
6 [45] P.W.J.C. Serruys, Y. Onuma, *Bioresorbable Scaffolds: From Basic Concept to*
7
8
9 *Clinical Applications*, CRC Press, 2017.
10

11 [46] M. Bornapour, H. Mahjoubi, H. Vali, D. Shum-Tim, M. Cerruti, M. Pekguleryuz,
12
13
14 *Surface characterization, in vitro and in vivo biocompatibility of Mg-0.3Sr-0.3Ca for*
15
16
17 *temporary cardiovascular implant, Mater. Sci. Eng. C. 67 (2016) 72-84.*
18

19 [47] H. Jinnouchi, S. Torii, A. Sakamoto, F.D. Kolodgie, R. Virmani, A.V. Finn, Fully
20
21
22 *bioresorbable vascular scaffolds: lessons learned and future directions, Nat. Rev.*
23
24
25 *Cardiol. 16(5) (2019) 286-304.*
26

27 [48] A. Lupi, A. Schaffer, A.S. Bongo, Should ultrathin strut drug eluting stents be
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

66 [49] C. Indolfi, S.D. Rosa, A. Colombo, *Bioresorbable vascular scaffolds - basic*
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1 Weissman, Early-and long-term intravascular ultrasound and angiographic findings
2
3 after bioabsorbable magnesium stent implantation in human coronary arteries, JACC:
4
5
6 Cardiovasc. Inte. 2(4) (2009) 312-320.

7
8
9 [52] M. Echeverry-Rendon, J.P. Allain, S.M. Robledo, F. Echeverria, M.C. Harmsen,
10
11 Coatings for biodegradable magnesium-based supports for therapy of vascular disease:
12
13 a general view, Mater. Sci. Eng. C. 102 (2019) 150-163.

14
15
16 [53] T.L. Pinto Slottow, R. Pakala, R. Waksman, Serial imaging and histology
17
18 illustrating the degradation of a bioabsorbable magnesium stent in a porcine coronary
19
20 artery, Eur. Heart J. 29(3) (2008) 314.

21
22
23 [54] E. Galvin, C. Cummins, S. Yoshihara, B.J. Mac Donald, C. Lally, Plastic strains
24
25 during stent deployment have a critical influence on the rate of corrosion in absorbable
26
27 magnesium stents, Med. Biol. Eng. Comput. 55(8) (2017) 1261-1275.

28
29
30 [55] Y.M. Gao, L.Z. Wang, L.H. Li, X.N. Gu, K. Zhang, J. Xia, Y.B. Fan, Effect of
31
32 stress on corrosion of high-purity magnesium in vitro and in vivo, Acta Biomater. 83
33
34 (2019) 477-486.

35
36
37 [56] C.X. Chen, J.H. Chen, W. Wu, Y.J. Shi, L. Jin, L. Petrini, L. Shen, G.Y. Yuan, W.J.
38
39 Ding, J.B. Ge, E.R. Edelman, F. Migliavacca, In vivo and in vitro evaluation of a
40
41 biodegradable magnesium vascular stent designed by shape optimization strategy,
42
43 Biomaterials 221 (2019) 119414.

44
45
46 [57] W. Wu, S.S. Chen, D. Gastaldi, L. Petrini, D. Mantovani, K. Yang, L.L. Tan, F.
47
48 Migliavacca, Experimental data confirm numerical modeling of the degradation
49
50 process of magnesium alloys stents, Acta Biomater. 9(10) (2013) 8730-8739.

1 [58] J. Wang, V. Giridharan, V. Shanov, Z.G. Xu, B. Collins, L. White, Y. Jang, J. Sankar,
2
3 N. Huang, Y. Yun, Flow-induced corrosion behavior of absorbable magnesium-based
4
5
6 stents, *Acta Biomater.* 10(12) (2014) 5213-5223.
7

8
9 [59] S.S. Chen, P. Wan, B.C. Zhang, D. Eren Erişen, H. Yang, K. Yang, A novel polymer
10
11
12 critical re-melting treatment for improving corrosion resistance of magnesium alloy
13
14
15 stent, *J. Mater. Sci. Technol.* 35(1) (2019) 19-22.
16

17 [60] J. Liu, B. Zheng, P. Wang, X.G. Wang, B. Zhang, Q.P. Shi, T.F. Xi, M. Chen, S.K.
18
19
20 Guan, Enhanced in vitro and in vivo performance of Mg-Zn-Y-Nd alloy achieved with
21
22
23 APTES pre-treatment for drug-eluting vascular stent application, *Acs Appl. Mater.*
24
25
26 *Interfaces* 8 (2016) 17842-17858.
27

28 [61] L. Mao, H. Zhou, L. Chen, J.L. Niu, L. Zhang, G.Y. Yuan, C.L. Song, Enhanced
29
30
31 biocompatibility and long-term durability in vivo of Mg-Nd-Zn-Zr alloy for vascular
32
33
34 stent application, *J. Alloy. Compd.* 720 (2017) 245-253.
35

36 [62] W. Wang, Y.L. W, M. Chen, L. Chen, J. Zhang, Y.D. Li, M.H. Li, G.Y. Yuan,
37
38
39 Magnesium alloy covered stent for treatment of a lateral aneurysm model in rabbit
40
41
42 common carotid artery: an in vivo study, *Sci. Rep.* 6 (2016) 37401.
43

44 [63] T.L. Pinto Slottow, R. Pakala, T. Okabe, D. Hellinga, R.J. Lovec, F.O. Tio, A.B.
45
46
47 Bui, R. Waksman, Optical coherence tomography and intravascular ultrasound imaging
48
49
50 of bioabsorbable magnesium stent degradation in porcine coronary arteries, *Cardiovasc.*
51
52
53 *Revasc. Med.* 9(4) (2008) 248-254.
54

55 [64] M. Haude, R. Erbel, P. Erne, S. Verheye, H. Degen, D. Böse, P. Vermeersch, I.
56
57
58 Wijnbergen, N. Weissman, F. Prati, R. Waksman, J. Koolen, Safety and performance of
59
60

1 the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo
2
3 coronary lesions: 12 month results of the prospective, multicentre, first-in-man
4
5 BIOSOLVE-I trial, *Lancet* 381(9869) (2013) 836-844.
6

7
8
9 [65] Y. Ozaki, H.M. Garcia-Garcia, E. Shlofmitz, A. Hideo-Kajita, R. Waksman,
10
11 Second-generation drug-eluting resorbable magnesium scaffold: review of the clinical
12
13 evidence, *Cardiovasc. Revasc. Med.* 21(1) (2020) 127-136.
14
15

16
17 [66] S.S. Chen, B. Zhang, B.C Zhang, H. Lin, H. Yang, F. Zheng, M. Chen, K. Yang,
18
19 Assessment of structure integrity, corrosion behavior and microstructure change of
20
21 AZ31B stent in porcine coronary arteries, *J. Mater. Sci. Technol.* 39 (2020) 39-47.
22
23

24
25 [67] J. Zhang, H.Y. Li, W. Wang, H. Huang, J. Pei, H.Y. Qu, G.Y. Yuan, Y.D. Li, The
26
27 degradation and transport mechanism of a Mg-Nd-Zn-Zr stent in rabbit common carotid
28
29 artery: a 20-month study, *Acta Biomater.* 69 (2018) 372-384.
30
31

32
33 [68] Y.J. Shi, L. Zhang, J.H. Chen, J. Zhang, F. Yuan, L. Shen, C.X. Chen, J. Pei, Z.H.
34
35 Li, J.Y. Tan, G.Y. Yuan, In vitro and in vivo degradation of rapamycin-eluting Mg-Nd-
36
37 Zn-Zr alloy stents in porcine coronary arteries, *Mater. Sci. Eng. C.* 80 (2017) 1-6.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Figure captions**
2
3

4 Figure 1 (a) Schematic pattern design of the Mg-8.5Li stent, (b) the FEA model
5 composed of a stent and one cylinder, (c) typical tensile curve of the Mg-8.5Li alloy.
6
7

8
9
10 Figure 2 (a) The distribution of principal strain and stress on the stent during balloon
11 dilation and natural recoil, with typical positions indicated.
12
13

14
15
16 Figure 3 Macroscopic morphologies of the stent (either dilated or not) before and after
17 immersion under an optical camera (upper) and under a micro-CT scanner (lower, after
18 immersion), with red arrows indicating the localized degradation sites.
19
20
21

22
23
24 Figure 4 Microscopic morphologies of the stent before and after removing the
25 degradation products under SEM, with enlargement of typical areas.
26
27
28

29
30
31 Figure 5 (a) Cross-sectional morphologies of the degraded stents and corresponding
32 EDS element mapping (red: Mg, green: O, blue: Ca, cyan: P, purple: C), (b) pH
33 variation during a 7-day immersion in Hank's solution at 37 °C, (c) element
34 concentrations (Mg, Li, Ca, P) in Hank's solution after immersion for 7 days, normal
35 Hank's solution as control, • $p < 0.05$, * $p < 0.01$.
36
37
38
39
40
41
42
43
44

45 Figure 6 (a) XPS spectrum, (b) FTIR spectrum, (c) XRD pattern, and (d) high resolution
46 narrow XPS scanning of the stent (after 7-day immersion in Hank's solution).
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Figure 7 (a) The implantation surgery and retrieval of stented vessels (a1: exposure of
2 the iliac artery, a2: stent deployment process, a3: laparotomy during sample retrieval,
3
4 a4: the retrieved iliac artery), (b) 3D reconstruction of the remaining stent from micro-
5
6 CT analysis, (c) typical histological images of the stented iliac arteries at different time
7
8 points, with normal iliac artery as control. Black triangles indicate the positions of the
9
10 stent struts, and possible absence of the struts was caused by the slicing process or H&E
11
12 staining procedure. Red arrows indicate the presence of debris or degradation products.
13
14
15
16
17
18
19
20 The long red arrow shows some of the tissues surrounding the struts were torn away
21
22 from their original positions during slicing procedure.
23

24
25
26 Figure 8 (a) The status of endothelial coverage on Mg-8.5Li stent after 1 month in iliac
27
28 artery of minipigs characterized by SEM (typical areas on the strut and in the
29
30 intermediate spaces of the struts were displayed, tiny particles were salt deposits
31
32 derived from the tissue fixation and dehydration process.), (b) typical *in-vivo* corrosion
33
34 morphology of the stent and corresponding EDS analysis at regions of interest.
35
36
37

38
39
40 Figure 9 (a) *In-vitro* degradation rates of previously reported Mg-based BDSs (with or
41
42 without coating, the columns of stents with coatings were in magenta) in different
43
44 mediums, data were from Refs.[57-59] (b) the *in-vivo* degradation periods of various
45
46 Mg-based BDSs in different animal models, data were collected from Refs.[25-27, 51,
47
48 60-65].
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table caption

Table 1 *In-vitro* and *in-vivo* performances of previously reported Mg-based BDSs for intravascular applications

Stent platform material	Strut thickness (µm)	Coating	<i>In-vitro</i> performance				<i>In-vivo</i> performance			Reference
			Dilation	Degradation medium	Static/dynamic degradation	<i>In-vitro</i> degradation	Animal model	<i>In-vivo</i> degradation	In vivo biocompatibility	
AZ31B	150	NA	Yes	D-Hanks' solution, for 14 days	Static	Broken into separate pieces in 14 days (characterized by a stereo microscope)	NA	NA	NA	2013[57]
AZ31	200	NA	Yes (from 4.5 mm to 6.3 mm)	DMEM+10% FBS+1% penicillin-streptomycin, in a bioreactor (5% CO ₂ , 95% RH) for 7 days	Static	0.37±0.07 mm/y (characterized by micro-CT)	NA	NA	NA	2014[58]
AZ31	200	NA	Yes (from 4.5 mm to 6.3 mm)	DMEM+10% FBS+1% penicillin-streptomycin, in a bioreactor (5% CO ₂ , 95% RH) for 7 days	Dynamic (with a flow-induced shear stress of 0.05Pa)	1.21 ± 0.27 mm/y (characterized by micro-CT)	NA	NA	NA	2014[58]
AZ31	140	A fluoride chemical conversional coating	NA	Hank's solution without Mg and Ca	Static	45% weight loss after 28 days	NA	NA	NA	2019[59]

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65




AZ31	140	A fluoride chemical conversional coating + PDLA coating	NA	Hank's solution without Mg and Ca	Static	<10% weight loss after 28 days	NA	NA	NA	2019[59]
AE21	150-200	NA	Yes (a stent/artery (diameter) ratio of 1.3)	NA	NA	NA	Pig coronary artery	Fully degraded in less than 90 days (characterized by measuring the strut cross-sectional area)	Significant narrowing (neointima formation) of lumen between days 10 and 35 caused by a short-period scaffolding	2003[25]
AZ31B	155	A P(LA-TMC) coating containing sirolimus	Yes (a stent/artery (diameter) ratio of 1.1~1.3)	NA	NA	NA	Rabbit infrarenal abdominal aorta	Full degradation in 6 months (characterized by measuring strut sectional area)	Reduced neointimal area, but delayed endothelialization compared to uncoated stent	2011[26]
AZ91	80-120	NA	Yes	NA	NA	NA	Coronary/femoral artery of dogs	Completely disappeared after 7 days (characterized by X-ray)	No thrombosis, and moderate intimal hyperplasia was found after 14 days	2015[27]
AZ31B	140	A fluoride chemical conversional coating + PDLA coating	Yes (a stent/artery (diameter) ratio of 1.1~1.2)	NA	NA	NA	Porcine coronary artery	More than 50% struts fractured (at the maximum stress site) after 1 month (characterized by X-ray tomography)	Completely embraced by neointima after 1 month and a slightly thicker intima, good blood compatibility and histocompatibility	2020[66]
Mg-2.0Zn-0.5Y-0.5Nd	150-180	A APTES silane physical barrier layer + a rapamycin-eluting PLGA coating	Yes (a stent/artery (diameter) ratio of 1.0-1.1)	NA	NA	NA	Porcine coronary artery	Stent strut mainly remained after 3 months, only limited strut residues was found after 6 months (characterized through histology)	Benign tissue compatibility as well as re-endothelialization without thrombogenesis or in-stent restenosis during 6-month followup	2016[60]
Mg-2.5Nd-0.21Zn-0.44Zr (JDBM)	150	NA	Yes	NA	NA	NA	Rabbit abdominal artery	Without the tube wall fractured after 4 months (characterized by micro-CT)	Excellent biocompatibility	2017[61]


16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


Mg-2.1Nd-0.21Zn-0.5Zr (JDBM)	150	NA	Yes (a stent/artery (diameter) ratio of 1.1~1.2)	NA	NA	NA	Rabbit common carotid artery	Some stent strut fractures after 1 month, stent struts broke into pieces after 4 months (characterized by micro-CT)	Good safety and efficacy with a complete re-endothelialization within 28 days, low risks of possible vessel calcification	2018[67]
Mg-2.1Nd-0.21Zn-0.5Zr (JDBM)	150	A bare stent (covered by an expandable e-PTFE membrane)	Yes	NA	NA	NA	Rabbit common carotid artery (a lateral aneurysm model)	Integrated stent structure was found after 2 weeks. The contour of the stent became vague after 6 months, and could not be visualized after 1 year (characterized by molybdenum target examination)	Disappearance of the aneurysms and patency of the carotid artery. The covered stents proved to be an effective approach for occlusion of lateral aneurysm in the rabbit common carotid artery	2016[62]
Mg-2.5Nd-0.2Zn-0.4Zr (JDBM)	150	A protective MgF ₂ layer + PDLA coating containing sirolimus	Yes (a stent/artery (diameter) ratio of 1.1)	NA	NA	NA	Porcine coronary artery	A remarkably lower degradation rate compared to bare stent, integral structure with only occasional fractures after 2 months (characterized by micro-CT)	Favorable safety with no occurrence of adverse complications, similar neointima proliferation compared to a commercial Firebird 2 DES	2017[68]
Mg-2.1Nd-0.2Zn-0.5Zr (JDBM)	150	A protective MgF ₂ layer + PLT base coating and PLGA top coating containing sirolimus	Yes	NA	NA	NA	Rabbit iliac artery	A volume loss of 64% after 5 months (characterized by micro-CT)	No thrombus or early restenosis, suitable biocompatibility	2019[56]
AMS, Biotronik (WE43)	165	NA	Yes	NA	NA	NA	Porcine coronary artery	Degraded over a 3-month time period (characterized by OCT and histology)	A progressive degradation of the stents, no significant increase in neointimal area.	2008[63]


AMS, Biotronik (WE43)	165	NA	Yes	NA	NA	NA	Human coronary artery	Nearly complete degradation at 4 months (characterized by IVUS)	Early recoil as a main contributor for restenosis at 4 months	2009[51]
DREAMS-1G, Biotronik (WE43)	120	A PLGA coating with paclitaxel	Yes	NA	NA	NA	Human coronary artery	Resorption time was within 6 months (characterized by OCT and IVUS)	A faster than expected stent degradation with an early loss of radial force and consequent vessel recoil.	2013[64]
DREAMS-2G/Magmaris, Biotronik (WE43)	150	A PLLA coating with sirolimus	Yes	NA	NA	NA	Human coronary artery	Scaffolding time up to 3 months and the resorption time prolonged to 12 months (characterized by OCT and IVUS)	Clinical evidence of safety and efficacy	2016-2020[20, 65]
Mg-0.3Sr-0.3Ca [#]	250	NA	Yes	NA	NA	NA	Femoral artery of Beagle dog	The wall thickness decreased from 250 μm to ~200 μm after 5 weeks (characterized by histology)	No sign of occlusion, no thrombosis, in situ formation of Sr-substituted HA on the stent surface	2016[46]
WE43	250	NA	Yes	NA	NA	NA	Femoral artery of Beagle dog	The wall thickness did not change significantly after 5 weeks (characterized by histology)	Artery was extensively occluded and thrombosed. Suspected to be related to rare-earth elements	2016[46]
Mg-8.5Li [#]	150	NA	Yes (a stent/artery (diameter) ratio of 1.06-1.17)	Hank's solution at 37±0.5 °C for 7 days	Static	0.145±0.031 mm/y (characterized by weight loss)	Porcine iliac artery	Degradation rate > 0.6 mm/y, scaffolding time less than 1 month, almost fully degraded in 3 months	No possible thrombus, fast endothelial coverage in 1-month, acceptable histocompatibility	Present work


PDLLA: poly(D,L-lactide), P(LA-TMC): poly(lactic acid-co-trimethylene carbonate), APTES: cross-linked 3-amino-propyltrimethoxysilane, PLGA: poly lactic-co-glycolic acid, PTFE: polytetrafluoroethylene, PLT: poly (l-lactide-co-trimethylene carbonate), PLLA: poly-l-lactide. #: rare earth-free and aluminum-free.

















Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: